Similarly, a study on a USP8 inhibitor demonstrated its effectiveness in suppressing pancreatic tumor growth by activating killer T cells, especially when combined with anti-PD-L1 therapy [81]. This evidence concerns the gene CD274 and pancreatic neoplasm.